Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over 190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis, agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting.